Trial Profile

A Phase 2b trial of ATI 052 for atopic dermatitis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 09 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BSI 502 (Primary)
Indications Atopic dermatitis
Focus Therapeutic Use

Most Recent Events

09 Jan 2026 New trial record
06 Jan 2026 According to an Aclaris Therapeutics media release, the company is planning to advance ATI-052 into a Phase 2b trial in atopic dermatitis (AD) in the second half of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com